FMC to Report Q1 Earnings: What's in the Cards for the Stock?
Werte in diesem Artikel
FMC Corporation FMC is set to release first-quarter 2025 results after the closing bell on April 30.The company beat the Zacks Consensus Estimate for earnings in each of the last four quarters. On average, FMC has a trailing four-quarter earnings surprise of around 20.2%. The company reported an earnings surprise of 11.1% in the last reported quarter.FMC is likely to have faced challenges from de-stocking and pricing pressures in the first quarter. The company's cost actions and new product launches are expected to have contributed to its performance.FMC’s shares have lost 29.5% in the past year compared with the Zacks Agriculture – Operations industry’s 6.7% decline.Image Source: Zacks Investment ResearchLet’s see how things are shaping up for this announcement.What Our Model Unveils for FMC StockOur proven model predicts an earnings beat for FMC this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earning beat.Earnings ESP: Earnings ESP for FMC is +34.04%. The Zacks Consensus Estimate for the first quarter is currently pegged at 8 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Zacks Rank: FMC currently carries a Zacks Rank #3.(Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)What Do FMC’s Revenue Estimates Say?The Zacks Consensus Estimate for first-quarter sales for FMC is currently pegged at $779 million, suggesting a 15.1% year-over-year decline.The consensus estimate for North America’s revenues is currently pegged at $224.2 million, suggesting a 13.4% year-over-year decline.The Zacks Consensus Estimate for Latin America sales is pegged at $137.9 million, indicating a 26.6% year-over-year decrease.The consensus estimates for Europe, the Middle East and Africa (EMEA) sales are pegged at $278.5 million, calling for a 9.2% year-over-year decline.The same for Asia is pinned at $144.8 million, indicating a 11.8% decline on a year-over-year basis.Factors at Play for FMC StockFMC is expected to have gained from efforts to expand its product portfolio through new product launches and restructuring actions in the first quarter. FMC is committed to strengthening its product portfolio by investing in new technologies and launching new products, which are gaining significant traction in Europe, North America and Asia. These initiatives are expected to have supported the company's results. The company is seeing strong performance of its growth portfolio, including Cyazypyr active and new active ingredients fluindapyr and Isoflex Active, which are generating higher sales. FMC is also expected to have benefited from reduced input costs, a favorable product mix and cost-control actions. It is making progress with its global restructuring and cost-reduction program. It saw benefits from restructuring of $165 million on full-year 2024 adjusted EBITDA, with more than $225 million run rate savings expected by the end of 2025. The benefits of restructuring actions are expected to be reflected in the company's margins in the quarter to be reported.The company is likely to have faced headwinds from inventory de-stocking. Continued active inventory management is expected to have weighed on its volumes. The company is seeing channel de-stocking in India and Latin America. FMC projects revenues for the first quarter to be in the $750-$800 million range, indicating a 16% decrease at the midpoint from the same period in 2024. Volume is projected to fall as customers in various countries continue to cut inventories and retailers and growers make cautious purchases in an environment of low commodity prices.Weaker prices are also likely to weigh on the company’s revenues in the first quarter. It faced headwinds from weaker prices in the fourth quarter. The pricing headwind is expected to have continued in the first quarter. FMC sees mid-to-high-single digit price decline in the first quarter mainly due to the price adjustments for diamide partner contracts.FMC Corporation Price and EPS Surprise FMC Corporation price-eps-surprise | FMC Corporation QuoteBasic Materials Stocks That Warrant a LookHere are some companies in the basic materials space you may want to consider as our model shows they too have the right combination of elements to post an earnings beat this quarter:CF Industries Holdings, Inc. CF, scheduled to release earnings on May 7, has an Earnings ESP of +3.67% and carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.The consensus estimate for CF’s earnings for the first quarter is currently pegged at $1.47.ATI Inc. ATI, slated to release earnings on May 1, has an Earnings ESP of +2.46% and carries a Zacks Rank #3 at present.The consensus mark for ATI’s first-quarter earnings is currently pegged at 58 cents.Kinross Gold Corporation KGC, scheduled to release earnings on May 6, has an Earnings ESP of +11.07%.The Zacks Consensus Estimate for Kinross Gold's earnings for the first quarter is currently pegged at 22 cents. KGC currently carries a Zacks Rank #2.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ATI Inc. (ATI): Free Stock Analysis Report CF Industries Holdings, Inc. (CF): Free Stock Analysis Report Kinross Gold Corporation (KGC): Free Stock Analysis Report FMC Corporation (FMC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: FMC und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf FMC
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf FMC
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Fresenius Medical Care (FMC) St.
Analysen zu Fresenius Medical Care (FMC) St.
Datum | Rating | Analyst | |
---|---|---|---|
23.04.2025 | Fresenius Medical Care (FMC) St Neutral | UBS AG | |
23.04.2025 | Fresenius Medical Care (FMC) St Buy | Goldman Sachs Group Inc. | |
22.04.2025 | Fresenius Medical Care (FMC) St Hold | Deutsche Bank AG | |
22.04.2025 | Fresenius Medical Care (FMC) St Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
22.04.2025 | Fresenius Medical Care (FMC) St Equal Weight | Barclays Capital |
Datum | Rating | Analyst | |
---|---|---|---|
23.04.2025 | Fresenius Medical Care (FMC) St Buy | Goldman Sachs Group Inc. | |
22.04.2025 | Fresenius Medical Care (FMC) St Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
12.03.2025 | Fresenius Medical Care (FMC) St Buy | Goldman Sachs Group Inc. | |
27.02.2025 | Fresenius Medical Care (FMC) St Kaufen | DZ BANK | |
25.02.2025 | Fresenius Medical Care (FMC) St Buy | Goldman Sachs Group Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
23.04.2025 | Fresenius Medical Care (FMC) St Neutral | UBS AG | |
22.04.2025 | Fresenius Medical Care (FMC) St Hold | Deutsche Bank AG | |
22.04.2025 | Fresenius Medical Care (FMC) St Equal Weight | Barclays Capital | |
16.04.2025 | Fresenius Medical Care (FMC) St Market-Perform | Bernstein Research | |
04.03.2025 | Fresenius Medical Care (FMC) St Market-Perform | Bernstein Research |
Datum | Rating | Analyst | |
---|---|---|---|
17.04.2025 | Fresenius Medical Care (FMC) St Underweight | JP Morgan Chase & Co. | |
21.03.2025 | Fresenius Medical Care (FMC) St Underperform | Jefferies & Company Inc. | |
04.03.2025 | Fresenius Medical Care (FMC) St Underperform | Jefferies & Company Inc. | |
26.02.2025 | Fresenius Medical Care (FMC) St Underweight | JP Morgan Chase & Co. | |
25.02.2025 | Fresenius Medical Care (FMC) St Underperform | Jefferies & Company Inc. |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Fresenius Medical Care (FMC) St. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen